References
- National Health Commission. The guidelines for the diagnosis and treatment of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection (Pilot 3rd version) [S/OL].(2020-01-22)[2020-01-22]. Available from: http://www.nhc.gov.cn/xcs/zhengcwj/202001/f492c9153ea9437bb587ce2ffcbee1fa/files/39e7578d85964dbe81117736dd789d8f.pdf.
- World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance[S/OL]. (2020-01-12)[2020-01-22]. Available from: https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf?sfvrsn=bc7da517_2&download=true.
- Li T, Qiu Z, Han Y, et al. Rapid loss of both CD4+ and CD8+ T lymphocyte subsets during the acute phase of severe acute respiratory syndrome. Chin Med J (Engl). 2003;116(7):985–987.
- Tai-sheng LI, Zhi-feng QIU, Yang HAN, et al. The alterations of T cell subsets of severe acute respiratory syndrome during acute phase. Chin J Lab Med. 2003;26(5):297–299.
- Taoran G, Yang H, Taisheng L, et al. Characteristics and prognostic value of peripheral blood T lymphocyte subsets in patients with severe influenza. Chin J Internal Med. 2020;59(3), doi:10.3760/cma.j.issn.0578-1426.2020.03.
- Mori I, Parizot C, Dorgham K, et al. Prominent plasmacytosis following intravenous immunoglobulin correlates with clinical improvement in Guillain–Barré syndrome. PLoS One. 2008;3(5):e2109, doi:10.1371/journal.pone.0002109.
- Hemming VG. Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin Diagn Lab Immunol. 2001;8(5):859–863. doi:10.1128/CDLI.8.5.859-863.2001.